title: Docetaxel 100 versus 80 mg/m2 as adjuvant treatments of early breast cancer: an exploratory analysis of a randomised trial.
authors.forename: P
authors.initials: P
authors.lastname: Bono
authors.forename: P-L
authors.initials: PL
authors.lastname: Kellokumpu-Lehtinen
authors.forename: T
authors.initials: T
authors.lastname: Alanko
authors.forename: R
authors.initials: R
authors.lastname: Kokko
authors.forename: R
authors.initials: R
authors.lastname: Asola
authors.forename: T
authors.initials: T
authors.lastname: Turpeenniemi-Hujanen
authors.forename: S
authors.initials: S
authors.lastname: Jyrkkiö
authors.forename: V
authors.initials: V
authors.lastname: Kataja
authors.forename: M
authors.initials: M
authors.lastname: Leinonen
authors.forename: H
authors.initials: H
authors.lastname: Joensuu
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D017024:Chemotherapy, Adjuvant; D000077143:Docetaxel; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D043823:Taxoids / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel